Characterization of Polycystic Ovary Syndrome Among Flo App Users Around the World

Tarun Jain (tjain@northwestern.edu)
Northwestern University Feinberg School of Medicine

Olivia Negris
Northwestern University Feinberg School of Medicine

Dannielle Brown
Northwestern University Feinberg School of Medicine

Isabel Galic
Northwestern University Feinberg School of Medicine

Rodion Salimgariev
Flo Health Inc.

Liudmila Zhaunova
Flo Health Inc

Research

Keywords: Polycystic ovary syndrome, PCOS, body mass index, BMI, bloating, hirsutism, menstrual cycle tracking

DOI: https://doi.org/10.21203/rs.3.rs-131934/v1

License: ☒ ① This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: Polycystic ovary syndrome (PCOS) is a complex and multi-faceted endocrine disorder that affects 5-20% of women. Literature is limited regarding potentially differing PCOS phenotypes among women around the world. Therefore, we used Flo app technology to understand the multifaceted characteristics of PCOS across several countries and identify contributing risk factors to the development of this condition.

Methods: Flo is a widely used female health and wellbeing app with period tracking functionality that provides a globally representative and medically unbiased perspective on PCOS symptomatology. A chatbot dialog on PCOS was subsequently administered on the Flo application (app) to users from 142 countries (with at least 100 respondents) who have the app running in English during September-October 2019.

Results: For analyses, we selected the five countries with the greatest number of respondents: US (n=243,238), UK (n=68,325), India (n=40,092), Philippines (n=35,131), and Australia (n=29,926). Bloating was the most frequently reported symptom among PCOS-positive women and appeared to be the main predictor of PCOS in our model (odds ratio 3·76 [95% CI 3·60-3·94]; p<0·0001). Additional top predictors of PCOS are high blood cholesterol and glucose levels. As BMI increased, the percentage of women who reported a physician-confirmed PCOS diagnosis also increased. However, women in India did not follow this trend.

Conclusions: Our findings are based on the largest known PCOS dataset and indicate that symptoms are more complex than previously understood. The most frequently reported symptoms (bloating, facial hirsutism, irregular cycles, hyperpigmentation, and baldness) are broader than those included in the Rotterdam criteria. Future work should reevaluate and refine the criteria utilized in PCOS diagnosis.

Introduction

Polycystic ovary syndrome (PCOS) is an endocrine disorder affecting 5-20% of women worldwide. It is characterized by excess androgen production, ovulatory dysfunction, and menstrual irregularities. Individuals with PCOS are at increased risk for metabolic abnormalities and type 2 diabetes mellitus, infertility, obstetrical complications, obesity, endometrial carcinoma, and mood disorders.¹ Thus, PCOS presents a significant public health concern and requires comprehensive and consistent diagnostic criteria to accurately diagnose and care for the affected population.²

Since the 1990 National Institutes of Health (NIH) PCOS conference, the syndrome has been recognized to have a spectrum of symptoms with some diagnostic criteria.³ In 2003, the Rotterdam consensus refined criteria widely used today, which requires the presence of at least two of the following: hyperandrogenism, ovulatory dysfunction, and polycystic ovaries on ultrasound.⁴,⁵ In contrast, the Androgen Excess Society (AES) supports that excess androgen is a critical feature of PCOS and defines
the condition as the presence of hyperandrogenism and ovarian dysfunction. The use of varying PCOS diagnostic criteria raises issues of compatibility for PCOS research worldwide, resulting in confusion within clinical practice and a “delay in progress in understanding the syndrome”. While ethnic variation of PCOS is becoming better understood, discrepancies exist and research on geographical location and environmental exposure in relation to PCOS symptomatology warrants further investigation.

Symptoms of hyperandrogenism include hirsutism, acne, androgenic alopecia, and virilization. Hirsutism is present in up to 80% of patients with hyperandrogenism and thus is the most commonly used clinical diagnostic criterion. Acne affects roughly 15–25% of patients with PCOS and varies with ethnicity. Moreover, ovulatory dysfunction typically refers to menstrual cycle irregularities and subfertility. One retrospective study followed 786 women with PCOS and found 66% reported infertility. Furthermore, PCOS is closely associated with obesity as 30-75% of PCOS patients are obese. Women who are obese are more likely to have severe hyperandrogenism, menstrual disturbances, and psychological disturbances in PCOS. Due to this worsened disease manifestation, overweight and obese women may be more likely to receive a PCOS diagnosis. Despite the known association between PCOS and obesity, the prevalence of obesity in women with PCOS differs by age, ethnicity, and geographical location. Research into variability of PCOS with regard to body mass index (BMI) is limited by the lack of population-based studies.

While it is established that PCOS may vary in clinical presentation, literature is limited regarding differing phenotypes across a globally representative sample. There is a need to better understand geographic variation in PCOS, and also to improve women's satisfaction with treatment of PCOS. A 2017 study found that over one-third of women spent over two years, visiting at least three medical providers, searching for a diagnosis. Additionally, only 25% of these women were satisfied with the recommendations they received. The inconsistency in diagnoses may be due to the lack of data on the presentation of PCOS from a medically unbiased sample. Previous literature has shown that the participant referral population has significant effects on the PCOS phenotype presented due to factors such as patient concern and access to care.

The use of innovative health and wellbeing apps such as Flo, provides an opportunity to estimate the characteristics of PCOS in a globally representative and medically unbiased population. Due to the geographically dispersed use of Flo, we are able to analyze PCOS symptomatology relative to country in order to better characterize PCOS and its differing phenotypes among users worldwide. This present study aims to use Flo app technology to understand the multifaceted characteristics of PCOS across several countries and identify contributing risk factors to the development of this condition.

Methods

Flo application description
Flo is one of the most popular AI-driven women’s health apps worldwide, with over 137 million users. The app encompasses solutions for girls and women at every stage of their life (start of menstruation, cycle tracking, preparation for conception, pregnancy, early motherhood, menopause). Flo functionality includes Health Assistant, which is a chatbot that proactively initiates a user dialogue on various health topics, analyzes users’ answers, and flags potential health issues that may require medical attention.

**Data collection**

Data related to PCOS symptoms and past diagnoses were obtained from the PCOS chatbot dialog available to Flo users during September-October 2019. The dialogue included 18 questions related to reproductive and general health. The PCOS dialog was released in English and was available to 5.4 million Flo users who have their app running in English. Both iOS and Android users participated in the questionnaire. Study inclusion criteria included women aged 18-44 years seeking to track their cycle or to conceive, who were not pregnant or after a pregnancy, and who were not on active contraception. Participant characteristics including age and BMI were also collected from Flo users during the sign-up process. All users in the study agreed to the use of their de-identified and aggregated data for research purposes. IRB approval for this study was obtained from Northwestern University.

**Data preparation**

A user dataset from the PCOS chatbot dialog was used to analyze the effect of PCOS symptoms as predictors of disease. A second dataset based on the results of the same chatbot dialog, which also included user BMI information, was used to analyze the impact of BMI on the odds ratio of having PCOS. Further analyses were conducted using only the data of women coming from the top five countries with the highest number of survey respondents.

**Statistical analysis**

Binary logistic regression was used as a statistical method. The diagnosis of PCOS was used as a dependent variable in the regression model. The dependent variable could have one of two values: ‘PCOS positive’ or ‘PCOS negative’ (the participants with an undefined diagnosis were not included in the model). Separate self-reported symptoms of the disease, with two possible levels of the variable – presence or absence of a symptom, were used as predictors to determine the odds ratio of PCOS and to estimate 95% confidence intervals (CI). A separate logistic model was created for individual predictors for each country and the total (of the top five countries) group.

To estimate the statistical significance of the difference in average weight between PCOS positive and PCOS negative groups, a two-sided t-test was used. To analyze the influence of BMI as a predictor of PCOS, participants were divided into six BMI groups with normal BMI (18.5-24.9) used as a reference. BMI was used as a dichotomous variable that can take one of two values: normal BMI and a comparable group (for example, 18.5-24.9 vs. 25.0-29.9) with subsequent relative odds ratio and 95% CI assessment.
Separate models were created for each of the BMI groups for each country and the total (of the top five countries) group. Statistical methods were implemented in Statsmodels and Scipy libraries of Python 3.

Results

The cohort includes responses from Flo users in 142 countries with at least 100 respondents in total. Most English-speaking Flo users who started the PCOS chatbot dialog were located in the US (n=243,238), followed by the UK (n=68,325), India (n=40,092), Philippines (n=35,131), and Australia (n=29,926); these countries are referred to as the top five based upon number of responding users. Of the top five cohort, 14.4% self-reported having PCOS that was previously diagnosed by a physician. 8.1% of users self-reported a negative PCOS status and 77.5% had not recently been checked by a physician, indicating that their PCOS status is unknown. Across all the users from the top five countries, the ratio of PCOS positive users to PCOS negative users was 1.8 (see Table 1). Among the top five countries, the highest ratio of PCOS positive users to PCOS negative users occurred in the Philippines (2.8), followed by India (1.9), UK (1.7), US (1.7), and Australia (1.5). Countries with at least 1,000 respondents with a confirmed PCOS diagnosis, but not included in the top five analyses with the highest ratios of PCOS positive to PCOS negative users were: Trinidad and Tobago (3.0), United Arab Emirates (2.2), Jamaica (1.8), New Zealand (1.5), and Pakistan (1.5) (see Table 2). As shown in Figure 1, a physician’s diagnosis of PCOS was most frequently reported in India (22.7%) followed by the Philippines (20.0%).

In the US, UK, and Australia, the most common symptoms of PCOS positive women were bloating, facial hirsutism, and irregular cycles (see Table 3). In the Philippines, women with PCOS were most likely to have bloating (75.4%), hyperpigmentation (68.5%), irregular cycle (64.4%), and baldness (61.0%). Women with PCOS in India most often reported baldness (74.4%), hyperpigmentation (66.5%), and irregular cycles (62.2%). In four of the top five countries, the most frequently reported symptom was bloating, seen in 73.8% of US women, 78.6% of UK women, 80.4% of women in Australia, and 75.4% of women in the Philippines with PCOS.

As indicated in Table 4, we examined the associations for predictors of self-reported PCOS according to symptom manifestation. Within the whole cohort of the top five countries, the most prevalent predictors of PCOS were bloating (OR: 3.8; 95% CI: 3.6-3.9; p<0.0001), both high cholesterol and glucose (OR: 3.6; 95% CI: 3.3-3.9; p<0.0001), and high glucose alone (OR: 2.9; 95% CI: 2.7-3.1; p<0.0001). Bloating was one of the most common predictors of self-reported PCOS among users in all countries with the exception of India. Likewise, having both high cholesterol and glucose was a strong predictor of self-reported PCOS among users in all countries with the exception of the Philippines. Users in India most commonly reported high cholesterol and glucose (OR: 2.8; 95% CI: 2.1-3.8; p<0.0001) followed by an irregular cycle (OR:2.8; 95% CI: 2.4-3.2; p<0.0001) and high glucose (OR: 2.6; 95% CI: 2.0-3.3; p<0.0001). In the US and Philippines, facial hirsutism was also a strong predictor of self-reported PCOS (OR: 1.2 and 3.6, respectively).
There was a statistically significant difference between overall mean BMI for PCOS positive users in the top five countries (27.7) and the overall mean BMI for PCOS negative users in the top five countries (26.2) (p<0·0001). Across all BMI groups, there is an observed trend that as BMI increased, the percentage of women with a self-reported PCOS diagnosis also increased (see Figure 2). While this percentage of women with PCOS increases, the percentage of women without a PCOS diagnosis stays relatively stable across BMI groups.

Compared to women of normal weight, women who are overweight, obese, severely obese, and morbidly obese all had a significantly increased odds of having a positive PCOS diagnosis in the top five cohort (see Table 5). There is again a positive trend relating this increased risk of presenting with PCOS and increasing BMI across the whole cohort.

In the US and UK, women who are obese and severely obese were at least twice as likely to have a positive PCOS diagnosis compared to women of normal weight (US: Obese OR: 2.1, Severely Obese OR: 2.5; UK: Obese OR: 2.2, Severely Obese OR = 2.2; p<0.05). A similar, but less pronounced, relationship exists for obese and severely obese women in Australia and the Philippines (Australia: Obese OR: 1.6, Severely Obese OR: 1.7; Philippines: Obese OR:1.8, Severely Obese OR: 2.4; p<0.05). The greatest risk exists for morbidly obese women in the UK as they had an over three times increase in odds of having a PCOS diagnosis compared to normal weight women (OR: 3.2; p<0.05). Interestingly, no significant relationship between BMI and odds of a PCOS diagnosis exist for women in India (Table 5).

**Discussion**

Using Flo’s technology, we analyzed the largest known PCOS symptom dataset to obtain a comprehensive understanding of the distribution of PCOS and its varying phenotypes worldwide. Among all countries, the highest ratio of PCOS positive to PCOS negative users occurred in Trinidad and Tobago, Philippines, United Arab Emirates, India, Jamaica, UK, followed by the US. The US, UK, India, Philippines and Australia had the greatest number of respondents to the PCOS dialog box. Within these top five countries, the most prevalent predictors of PCOS were bloating, both high cholesterol and glucose, and high glucose alone. Additionally, among four of the top five countries, bloating was the most frequently reported symptom. When examining BMI in relation to PCOS, there is a trend that as BMI increased, the percentage of women with a self-reported PCOS diagnosis also increased. However, women in India did not follow this trend as there was no significant relationship between BMI and PCOS status.

Previous research on global PCOS symptomatology is both limited and inconsistent. Many have identified South Asian women to have among the lowest prevalence rates, yet this group has been found to have high rates of insulin resistance and metabolic syndrome. Another study found that 52% of women residing in India present with PCOS, which is the highest reported prevalence internationally. Consistent with this report, our findings show that India and the Philippines were among the top countries with high ratios of PCOS positive to PCOS negative users. Another study analyzing PCOS phenotypes among different populations reported that women with PCOS from Asia and America were at increased
risk of type II diabetes. Their PCOS is most often characterized by insulin resistance, high BMI, or central obesity while Europeans and Middle Eastern women often experience androgenic alopecia, hirsutism, and hyperandrogenism. In our sample from India, individuals who reported both high cholesterol and high glucose were almost three times more likely to self-report having PCOS. However, respondents in the US and UK with symptoms of both high cholesterol and high glucose were almost four times more likely, and those in Australia almost five times more likely to report PCOS. Moreover, East Asian women with PCOS often have a milder hyperandrogenic phenotype and lower BMI compared to others, but have the highest prevalence of metabolic syndrome. Kumarapeli et al studied a semi urban population in Sri Lanka and found that of women with self-reported oligo/amenorrhea or hirsutism, over 90% had a confirmed PCOS diagnosis. These women tend to have less hirsutism compared to women from Europe and the US.

It is known that the prevalence of PCOS is increased in overweight and obese women, and that obesity prevalence has globally increased in the last few decades. Our results also reveal that as BMI increased, the proportion of women with a PCOS diagnosis also increased. However, obesity prevalence is highly variable by age, ethnicity, and geographical location. In the US and UK, obese women were twice as likely to have PCOS compared to those of normal weight; while there were no observed trends in BMI and odds of PCOS diagnosis in India. Geographic differences in the prevalence of obesity is likely a result of the interaction between individual factors (e.g. genetic) and environmental factors (e.g. food supply). A previous meta-analysis indicated that an increased risk of obesity exists for Caucasian women from the US and Europe compared to Asian women from China and Taiwan, suggesting a difference in the nature of PCOS based on location. Understanding such geographical differences in PCOS as it relates to BMI is critical for countries where increased obesity exists, as overweight and obese PCOS patients are more likely to exhibit clinical signs of androgen excess, significantly more severe insulin resistance, as well as anxiety and depression.

Compared to the NIH diagnostic criteria, the more expansive definition and inclusion of additional phenotypes of the Rotterdam and AES criteria may explain the greater estimates of PCOS prevalence. When using the same defining criteria, variations in the reported prevalence across countries can in part be explained by ethnic differences, by the approaches used to define study population(s), and the application of varying methods to evaluate key PCOS features. In surveying the largest known sample on identified PCOS symptoms, we are able to provide evidence that the symptomatology may be more complex than previously understood. Within the top five countries, our most frequently reported symptoms were bloating, facial hirsutism, irregular cycles, hyperpigmentation, and baldness. The symptoms reported in our sample are broader than those included in the Rotterdam criteria, suggesting more work and further research is needed to reevaluate and refine PCOS diagnostic criteria. Also, the most frequently reported symptoms of PCOS varied across countries, suggesting the presence of environmental and/or genetic effects on the PCOS phenotype. Interestingly, we found that symptoms were similar between US/UK and between India/Philippines - countries that are socio-demographically similar.
Gynecological and reproductive education delivered through apps has potential to improve physician to patient interactions, while also providing large quantities of menstrual cycle and related data. There are over a hundred female health and wellbeing apps with more than 200 million downloads. As such, medical professionals and researchers can gather information from large, unselected patient populations like ours in order to improve the understanding of gynecological disorders such as PCOS. Flo and other fertility apps can also provide public health benefits by offering standardized health promotion messages during various stages of reproductive life.

Strengths of our study included a very large global sample of medically unbiased women. A limitation is that women who already have certain medical conditions may have been more likely to participate in the dialog. In addition to the fact data were self-reported, women who said they did not have a physician-confirmed PCOS diagnosis may have another reproductive disorder which might be symptomatically similar to PCOS. It is also possible that different countries use different diagnostic criteria and medical professionals may have different approaches to PCOS diagnosis. Lastly, the dialog was available to Flo users running the app in English, which limited representation especially in countries that are not predominantly English speaking.

Via analysis of a worldwide PCOS dataset, we obtained a more comprehensive understanding of the distribution of PCOS and its varying phenotypes. The most frequently reported symptoms were bloating, facial hirsutism, irregular cycles, hyperpigmentation, and baldness, which are broader than those included in the Rotterdam criteria. Future work should reevaluate and consider refining criteria utilized in diagnosing and caring for the many women with PCOS around the world.

**List Of Abbreviations**

Polycystic ovary syndrome (PCOS), National Institutes of Health (NIH), Androgen Excess Society (AES), body mass index (BMI)

**Declarations**

*Ethics Approval and Consent to Participate:* Northwestern IRB Approval STU00210811.

*Consent for Publication:* Not applicable.

*Availability of Data and Materials:* The data that support the findings of this study are available from Flo Health Inc. but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of Flo Health Inc.

*Competing Interests:* The authors report no conflicts of interest.

*Funding:* Not applicable.
Authors’ Contributions: TJ, ON, DB, and IG made substantial contributions to the conception and design, interpretation of data, drafted and reviewed the article critically for important intellectual content. LZ and RS made substantial contributions to the conception and design, analyzed and interpreted study data, and critically reviewed the manuscript. All authors provided final approval of the manuscript and agreed to be accountable for all aspects of the work related to its accuracy and integrity.

Acknowledgements: We thank the Flo Medical and Scientific Affairs team for their critical review and feedback on the manuscript.

References

1. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
2. March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2009;25(2):544–51.
3. Group TREA-SPCW. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.
4. Bani Mohammad M, Majdi Seghinsara A. Polycystic Ovary Syndrome (PCOS), Diagnostic Criteria, and AMH. Asian Pacific journal of cancer prevention: APJCP. 2017;18(1):17–21.
5. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev. 2015;36(5):487–525.
6. Azziz R, Carmina E, Dewailly D, et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. The Journal of Clinical Endocrinology Metabolism. 2006;91(11):4237–45.
7. Health NIo. Evidence-based Methodology Workshop on Polycystic Ovary Syndrome (PCOS). Pathways to Prevention Workshop Program (P2P): National Institutes of Health, 2012.
8. Yildiz BO. Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinol Metab. 2006;20(2):167–76.
9. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.
10. Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil (Camb). 2000;3(2):101–5.
11. Al-Azemi M, Omu FE, Omu AE. The effect of obesity on the outcome of infertility management in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2004;270(4):205–10.
12. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. International Journal of Obesity. 2007;31(2):8–13.
13. Kiddy D, Sharp P, White D, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol. 1990;32(2):213–20.

14. Holte J, Bergh T, Gennarelli G, Wide L. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotrophins and sex steroids in premenopausal women. Clin Endocrinol. 1994;41(4):473–81.

15. Balen AH, Conway GS, Kaltsas G, et al. Andrology: Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Human reproduction. 1995;10(8):2107–11.

16. Liou T-H, Yang J-H, Hsieh C-H, Lee C-Y, Hsu C-S, Hsu M-I. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertility sterility. 2009;92(6):1960–5.

17. Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Human Reproduction Update. 2018;24(4):455–67.

18. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update. 2012;18(6):618–37.

19. Reynolds K, Gu D, Whelton PK, et al. Prevalence and risk factors of overweight and obesity in China. Obesity. 2007;15(1):10–8.

20. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. Jama. 2010;303(3):235–41.

21. Cree-Green M. Worldwide Dissatisfaction With the Diagnostic Process and Initial Treatment of PCOS. J Clin Endocrinol Metab. 2017;102(2):375–8.

22. Ezeh U, Yildiz BO, Azziz R. Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome. J Clin Endocrinol Metab. 2013;98(6):E1088-96.

23. Zhao Y, Qiao J. Ethnic differences in the phenotypic expression of polycystic ovary syndrome. Steroids. 2013;78(8):755–60.

24. Wolf WM, Wattick RA, Kinkade ON, Olfert MD. Geographical Prevalence of Polycystic Ovary Syndrome as Determined by Region and Race/Ethnicity. Int J Environ Res Public Health 2018; 15(11).

25. Ding T, Hardiman PJ, Petersen I, Wang FF, Qu F, Baio G. The prevalence of polycystic ovary syndrome in reproductive-aged women of different ethnicity: a systematic review and meta-analysis. Oncotarget. 2017;8(56):96351–8.

26. Mani H, Davies MJ, Bodicoat DH, et al. Clinical characteristics of polycystic ovary syndrome: investigating differences in White and South Asian women. Clin Endocrinol (Oxf). 2015;83(4):542–9.

27. Casarini L, Brigante G. The Polycystic Ovary Syndrome Evolutionary Paradox: a Genome-Wide Association Studies–Based, in silico, Evolutionary Explanation. The Journal of Clinical Endocrinology Metabolism. 2014;99(11):E2412-E20.
28. Kumarapeli V, Seneviratne Rde A, Wijeyaratne CN, Yapa RM, Dodampahala SH. A simple screening approach for assessing community prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. Am J Epidemiol. 2008;168(3):321–8.

29. Álvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF. Prevalence and Characteristics of the Polycystic Ovary Syndrome in Overweight and Obese Women. Arch Intern Med. 2006;166(19):2081–6.

30. von Ruesten A, Steffen A, Floegel A, et al. Trend in obesity prevalence in European adult cohort populations during follow-up since 1996 and their predictions to 2015. PloS one. 2011;6(11):e27455.

31. Cameron AJ, Welborn TA, Zimmet PZ, et al. Overweight and obesity in Australia: the 1999–2000 Australian Diabetes, Obesity and Lifestyle Study (AusDiab). Med J Aust. 2003;178(9):427–32.

32. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. Jama. 2010;303(3):235–41.

33. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. The Lancet. 2011;378(9793):804–14.

34. Yuan C, Liu X, Mao Y, Diao F, Cui Y, Liu J. Polycystic ovary syndrome patients with high BMI tend to have functional disorders of androgen excess: a prospective study. J Biomed Res. 2016;30(3):197–202.

35. Liang SJ, Liou TH, Lin HW, Hsu CS, Tzeng CR, Hsu MI. Obesity is the predominant predictor of impaired glucose tolerance and metabolic disturbance in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2012;91(10):1167–72.

36. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. The journal of clinical endocrinology metabolism. 1999;84(1):165–9.

37. Ehrmann DA, Liljenquist DR, Kasza K, et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology Metabolism. 2006;91(1):48–53.

38. Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: a review. Obstet Gynecol Surv. 2006;61(11):723–32.

39. Barry JA, Kuczmierczyk AR, Hardiman PJ. Anxiety and depression in polycystic ovary syndrome: a systematic review and meta-analysis. Human reproduction. 2011;26(9):2442–51.

40. Sirmans SM, Parish RC, Blake S, Wang X. Epidemiology and comorbidities of polycystic ovary syndrome in an indigent population. J Investig Med. 2014;62(6):868–74.

41. Lizneva D, Suturina L, Walker W, Brakta S, Gavrilova-Jordan L, Azziz R. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.

42. Torous J, Nicholas J, Larsen ME, Firth J, Christensen H. Clinical review of user engagement with mental health smartphone apps: evidence, theory and improvements. Evid Based Ment Health. 2018;21(3):116–9.
43. Bull JR, Rowland SP, Scherwitzl EB, Scherwitzl R, Danielsson KG, Harper J. Real-world menstrual cycle characteristics of more than 600,000 menstrual cycles. npj Digital Medicine. 2019;2(1):83.
44. Dreaper J. Women warned about booming market in period tracker apps. BBC News. 2016 August 11, 2016.

**Tables**

**Table I.** Demographic and PCOS diagnosis status among responding Flo app users

|                        | Mean Age ± SD | Mean BMI ± SD | PCOS Diagnosed (n, %) | PCOS not Diagnosed (n, %) | PCOS Status Unknown (n, %) | Ratio PCOS (+) / PCOS (-) |
|------------------------|---------------|---------------|------------------------|---------------------------|---------------------------|--------------------------|
| Overall (top 5 countries) | 27.2 ± 5.82   | 25.64 ± 5.6   | 59871 (14.37)          | 33824 (8.11)              | 323017 (77.52)            | 1.77                     |
| United States          | 27.3 ± 5.97   | 26.31 ± 5.74  | 29619 (12.18)          | 18002 (7.4)               | 195617 (80.42)            | 1.65                     |
| United Kingdom         | 29.7 ± 5.97   | 25.07 ± 5.31  | 9387 (13.73)           | 5421 (7.93)               | 53517 (78.33)             | 1.73                     |
| India                  | 25.02 ± 4.71  | 23.76 ± 4.74  | 9096 (22.69)           | 4721 (11.78)              | 26275 (65.54)             | 1.93                     |
| Australia              | 27.28 ± 5.77  | 25 ± 5.32     | 4747 (15.86)           | 3149 (10.52)              | 22030 (73.61)             | 1.51                     |
| Philippines            | 24.7 ± 5.45   | 23.33 ± 4.69  | 7022 (19.99)           | 2531 (7.2)                | 25578 (72.81)             | 2.77                     |

**Table II.** Countries with at least 1000 PCOS negative and PCOS positive responding users altogether, ordered by PCOS (+) / PCOS (-) ratio
| Country                  | PCOS Not Diagnosed | PCOS Diagnosed | Total | Ratio PCOS (+) / PCOS (-) |
|-------------------------|--------------------|----------------|-------|--------------------------|
| Trinidad and Tobago     | 369                | 1110           | 1479  | 3.01                     |
| Philippines             | 2531               | 7022           | 9553  | 2.77                     |
| United Arab Emirates    | 569                | 1225           | 1794  | 2.15                     |
| India                   | 4721               | 9096           | 13817 | 1.93                     |
| Jamaica                 | 433                | 764            | 1197  | 1.76                     |
| United Kingdom          | 5421               | 9387           | 14808 | 1.73                     |
| United States           | 18002              | 29619          | 47621 | 1.65                     |
| Australia               | 3149               | 4747           | 7896  | 1.51                     |
| New Zealand             | 516                | 763            | 1279  | 1.48                     |
| Pakistan                | 1109               | 1617           | 2726  | 1.46                     |
| Canada                  | 2457               | 3361           | 5818  | 1.37                     |
| Malaysia                | 606                | 765            | 1371  | 1.26                     |
| Indonesia               | 719                | 866            | 1585  | 1.2                      |
| South Africa            | 987                | 1154           | 2141  | 1.17                     |
| Ireland                 | 501                | 572            | 1073  | 1.14                     |
| Nigeria                 | 743                | 661            | 1404  | 0.89                     |
| Romania                 | 624                | 440            | 1064  | 0.71                     |

**Table III.** Prevalence of symptoms among women with PCOS from the top 5 responding countries
| Symptom                                        | Whole cohort, % | United States, % | United Kingdom, % | Australia, % | Philippines, % | India, % |
|-----------------------------------------------|-----------------|------------------|-------------------|--------------|----------------|----------|
| Hirsutism                                     | 23.01           | 24.4             | 20.69             | 21.25        | 28.4           | 18.19    |
| Facial hirsutism                              | 65.47           | 73.03            | 64.2              | 63.18        | 51.07          | 53.31    |
| Trying to conceive more than year             | 41.54           | 40.57            | 40.71             | 29.41        | 54.97          | 37.27    |
| Family PCOS anamnesis                         | 31.83           | 34.55            | 32.37             | 37.16        | 32.76          | 20.52    |
| Bloating                                      | 71.6            | 73.82            | 78.62             | 80.41        | 75.37          | 47.56    |
| Baldness                                      | 45.2            | 34.17            | 33.21             | 30.91        | 61.03          | 74.39    |
| Irregular cycle                               | 68.14           | 71.38            | 69.31             | 70.74        | 64.43          | 62.23    |
| High glucose                                  | 11.52           | 14.86            | 7.68              | 10.9         | 7.65           | 6.85     |
| High cholesterol                              | 13.09           | 16.28            | 8.22              | 14.81        | 11.7           | 6.96     |
| High cholesterol and glucose                  | 12.77           | 18.49            | 5.57              | 11.81        | 11.61          | 4.99     |
| Hyperpigmentation                             | 59.96           | 60.26            | 52.51             | 47.54        | 68.46          | 66.53    |
| Heavy periods                                 | 55.22           | 63.37            | 63.11             | 54.97        | 42.57          | 30.56    |
| Acne                                          | 34.72           | 37.3             | 32.09             | 34.94        | 33.04          | 31.86    |

Key: The top 3 most prevalent symptoms for each country are highlighted in red

Table IV. Odds of having PCOS among women with self-reported symptoms compared to symptomless women
|                      | Whole cohort | United States | United Kingdom | Australia | Philippines | India  |
|----------------------|--------------|---------------|----------------|-----------|-------------|--------|
| Hirsutism            | 1.36         | 1.59          | 0.94           | 1.15      | 1.77        | 1.06   |
|                      | (1.30-1.43)  | (1.48-1.71)   | (0.83-1.06)    | (0.97-1.35) | (1.54-2.03) | (0.94-1.20) |
|                      | ****         | ****          | ns             | ns        | ****        | ns     |
| Facial hirsutism     | 2.43         | 3.10          | 1.76           | 1.98      | 3.61        | 2.10   |
|                      | (2.36-2.51)  | (2.96-3.23)   | (1.63-1.90)    | (1.79-2.19) | (3.21-4.06) | (1.94-2.28) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| Trying to conceive more than year | 1.67          | 2.17          | 1.44           | 1.25      | 1.13        | 1.27   |
|                      | (1.50-1.85)  | (1.84-2.55)   | (1.11-1.85)    | (0.83-1.88) | (0.86-1.50) | (0.98-1.63) |
|                      | ****         | ****          | **             | ns        | ns          | ns     |
| PCOS family history  | 1.99         | 2.24          | 1.68           | 1.64      | 2.39        | 1.84   |
|                      | (1.91-2.07)  | (2.11-2.37)   | (1.53-1.85)    | (1.45-1.86) | (2.08-2.74) | (1.63-2.07) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| Bloating             | 3.76         | 5.00          | 3.20           | 3.01      | 4.14        | 2.44   |
|                      | (3.60-3.94)  | (4.69-5.33)   | (2.85-3.59)    | (2.57-3.53) | (3.48-4.91) | (2.15-2.77) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| Baldness             | 2.18         | 2.32          | 1.92           | 1.86      | 2.32        | 2.31   |
|                      | (2.20-2.27)  | (2.18-2.48)   | (1.72-2.13)    | (1.60-2.16) | (2.07-2.59) | (2.11-2.52) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| Irregular cycle      | 2.77         | 2.92          | 2.41           | 3.39      | 2.99        | 2.76   |
|                      | (2.59-2.97)  | (2.63-3.24)   | (2.03-2.86)    | (2.63-4.37) | (2.45-3.66) | (2.35-3.23) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| High glucose         | 2.88         | 2.92          | 3.90           | 2.94      | 3.00        | 2.57   |
|                      | (2.67-3.12)  | (2.66-3.21)   | (2.95-5.16)    | (2.27-3.81) | (2.07-4.35) | (2.01-3.28) |
|                      | ****         | ****          | ****           | ****      | ****        | ****   |
| Condition                     | Country 1 | Country 2 | Country 3 | Country 4 | Country 5 | Country 6 |
|-------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| High cholesterol              | 1.39      | 1.41      | 1.79      | 1.48      | 1.13      | 1.25      |
|                               | (1.31-1.47)| (1.31-1.51)| (1.46-2.19)| (1.23-1.77)| (0.91-1.40)| (1.03-1.51) |
|                               | ****      | ****      | ****      | ns        | **        | ****      |
| High cholesterol and glucose  | 3.56      | 3.86      | 3.79      | 4.99      | 2.58      | 2.81      |
|                               | (3.26-3.88)| (3.48-4.29)| (2.70-5.33)| (3.58-6.96)| (1.90-3.51)| (2.06-3.83) |
|                               | ****      | ****      | ****      | ****      | ****      | ****      |
| Hyperpigmentation             | 2.26      | 2.42      | 2.10      | 2.09      | 2.48      | 1.76      |
|                               | (2.20-2.33)| (2.32-2.52)| (1.95-2.26)| (1.88-2.31)| (2.25-2.73)| (1.63-1.90) |
|                               | ****      | ****      | ****      | ****      | ****      | ****      |
| Heavy periods                 | 1.59      | 1.87      | 1.56      | 1.52      | 1.44      | 1.48      |
|                               | (1.55-1.64)| (1.79-1.94)| (1.45-1.67)| (1.38-1.67)| (1.31-1.59)| (1.36-1.61) |
|                               | ****      | ****      | ****      | ****      | ****      | ****      |
| Acne                          | 1.82      | 2.11      | 1.42      | 1.38      | 1.96      | 1.80      |
|                               | (1.74-1.90)| (1.97-2.25)| (1.27-1.59)| (1.19-1.60)| (1.70-2.27)| (1.61-2.02) |
|                               | ****      | ****      | ****      | ****      | ****      | ****      |

Data presented as: Odd ratio (95% CI)

ns = P > 0.05, * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001

Key: The top 3 highest odds of self-reported symptoms for each country are highlighted in red, while non-significant odds are highlighted in yellow

**Table V.** Odds of having PCOS between different BMI groups compared to women with normal BMI (reference group)
| Whole cohort | United States | United Kingdom | Australia | India | Philippines |
|--------------|---------------|----------------|-----------|-------|-------------|
| <18.5        | 0.93 (0.81-1.06) | 0.76 (0.51-1.12) | 0.77 (0.48-1.24) | 0.97 (0.75-1.26) | 0.90 (0.61-1.33) |
|              | ns *          | ns             | ns        | ns    | ns          |
| 18.5-24.9    | Reference group | Reference group | Reference group | Reference group | Reference group |
| 25-29.9      | 1.33 (1.24-1.42) | 1.60 (1.31-1.95) | 1.41 (1.12-1.78) | 1.12 (0.96-1.30) | 1.16 (0.91-1.47) |
|              | ****          | ****           | **        | ns    | ns          |
| 30.0-34.9    | 1.66 (1.53-1.79) | 2.15 (1.71-2.70) | 1.60 (1.22-2.10) | 1.18 (0.94-1.48) | 1.76 (1.20-2.57) |
|              | ****          | ****           | ***       | ns    | **          |
| 35-39.9      | 1.89 (1.73-2.07) | 2.24 (1.68-2.97) | 1.74 (1.27-2.40) | 1.27 (0.85-1.90) | 2.43 (1.23-4.82) |
|              | ****          | ****           | ***       | ns    | *           |
| >=40         | 2.04 (1.81-2.31) | 3.22 (2.07-5.00) | 1.91 (1.22-2.99) | 0.85 (0.43-1.67) | 0.41 (0.15-1.11) |

Data presented as: Odd ratio (95% CI)

ns = P > 0.05 (red), * = P ≤ 0.05, ** = P ≤ 0.01, *** = P ≤ 0.001, **** = P ≤ 0.0001

Key: The non-significant odds are highlighted in red